13F Holdings
中文EN

ALC ALCON INC IFRS

Ophthalmic Goods · NYSE · SEC CIK 1167379 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY4.9%
TTM net income YoY-3.7%
TTM EPS YoY-3.4%
Revenue 3-yr CAGR6.1%
Net income 3-yr CAGR43.0%

Margins

Gross margin55.2%
Operating margin13.1%
Net margin9.4%
FCF margin16.6%
EBITDA margin—

Returns

ROE4.5%
ROA3.2%
ROIC (approx.)4.6%
Asset turnover0.34x

Leverage & solvency

Liabilities / assets30.2%
Debt / equity0.21x
Current ratio2.12x
Interest coverage6.67x

Cash quality & payout

Operating cash flow / net income2.32x
Accruals ratio-4.2%
Payout ratio16.9%
Capex / revenue5.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$10.40B$9.91B$9.46B$8.72B$8.29B
Cost of revenue$4.59B$4.33B$4.14B$3.91B$3.58B
Gross profit$5.75B$5.51B$5.25B$4.75B$4.65B
R&D expense$990.00M$876.00M$828.00M$702.00M$842.00M
SG&A expense$3.45B$3.25B$3.21B$3.07B$3.08B
Operating income$1.36B$1.41B$1.04B$672.00M$580.00M
Interest expense$204.00M$192.00M$189.00M$134.00M$120.00M
Pretax income$1.16B$1.26B$832.00M$463.00M$418.00M
Income tax$180.00M$238.00M-$142.00M$128.00M$42.00M
Net income$980.00M$1.02B$974.00M$335.00M$376.00M
EPS (basic)1.992.061.980.680.77
EPS (diluted)1.982.051.960.680.76
Weighted avg. shares (diluted)496.20M497.50M496.50M494.40M493.40M
Balance sheet
Cash & equivalents$1.53B$1.68B$1.09B$980.00M$1.57B
Short-term investments$80.00M$153.00M$0$0$3.00M
Receivables$1.94B$1.74B$1.77B$1.67B$1.50B
Inventory$2.39B$2.27B$2.32B$2.11B$1.90B
Current assets$6.45B$6.31B$5.65B$5.19B$5.39B
PP&E, netmay include right-of-use assets (IFRS)$4.77B$4.39B$4.37B$4.03B$3.71B
Goodwill$9.26B$8.95B$8.93B$8.93B$8.90B
Intangibles$9.01B$8.59B$9.06B$9.69B$8.77B
Total assets$31.55B$30.35B$29.61B$29.16B$28.00B
Current liabilities$3.05B$2.28B$2.40B$2.74B$2.47B
Short-term debt$575.00M$105.00M$63.00M$107.00M$114.00M
Long-term debt$4.16B$4.54B$4.68B$4.54B$3.97B
Total debt$4.74B$4.64B$4.74B$4.65B$4.08B
Total liabilities$9.52B$8.79B$8.99B$9.49B$8.74B
Shareholders' equity$22.03B$21.55B$20.62B$19.68B$19.26B
Net debt$3.21B$2.97B$3.65B$3.67B$2.50B
Cash flow statement
Operating cash flow$2.27B$2.08B$1.39B$1.22B$1.34B
Capital expenditure$543.00M$473.00M$658.00M$636.00M$700.00M
Free cash flow$1.73B$1.60B$730.00M$581.00M$645.00M
Investing cash flow-$1.34B-$1.17B-$1.09B-$1.86B-$1.20B
Financing cash flow-$1.12B-$322.00M-$211.00M-$8.00M-$123.00M
Stock-based compensation$171.00M$162.00M$159.00M$152.00M$151.00M
Dividends paid$166.00M$130.00M$116.00M$100.00M$54.00M
Share buybacks$676.00M$0$0——

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.